SAB Biotherapeutics (SABS) Insider Trading & Ownership $2.80 -0.01 (-0.36%) (As of 11:34 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SAB Biotherapeutics (NASDAQ:SABS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage26.46%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$1,531.20Number OfInsiders Selling(Last 12 Months)0 Get SABS Insider Trade Alerts Want to know when executives and insiders are buying or selling SAB Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SABS Insider Buying and Selling by Quarter Ad Darwin2025: Digital Asset Insights You Need to KnowCryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.Get your guide today! SAB Biotherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/7/2023Eddie Joe SullivanCEOBuy1,740$0.88$1,531.20 (Data available from 1/1/2013 forward) SABS Insider Trading Activity - Frequently Asked Questions Who is on SAB Biotherapeutics's Insider Roster? The list of insiders at SAB Biotherapeutics includes Christine E Hamilton, Eddie Joe Sullivan, Michael King, and Samuel J Reich. Learn more on insiders at SABS. What percentage of SAB Biotherapeutics stock is owned by insiders? 26.46% of SAB Biotherapeutics stock is owned by insiders. Learn more on SABS's insider holdings. Which SAB Biotherapeutics insiders have been buying company stock? The following insiders have purchased SABS shares in the last 24 months: Eddie Joe Sullivan ($1,531.20), Michael King ($4,500.00), and Samuel J Reich ($9,790.00). How much insider buying is happening at SAB Biotherapeutics? Insiders have purchased a total of 17,740 SABS shares in the last 24 months for a total of $15,821.20 bought. SAB Biotherapeutics Key ExecutivesMr. Samuel J. Reich (Age 49)CEO & Executive Chairman Compensation: $363.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President & Director Compensation: $402.56kMs. Christine E. Hamilton M.B.A. (Age 68)Co-Founder & Independent Director Compensation: $25kMr. Michael George King Jr. (Age 63)EVP & CFO Compensation: $60.58kDr. Christoph Bausch M.B.A. (Age 53)Ph.D., Executive VP & COO Compensation: $443.2kDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Executive VP & Chief Medical Officer Compensation: $774.45kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverDr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory Affairs More Insider Trading Tools from MarketBeat Related Companies AGEN Insider Trading FBIO Insider Trading CRIS Insider Trading BOLT Insider Trading MTEM Insider Trading AMGN Insider Trading VRTX Insider Trading GILD Insider Trading REGN Insider Trading ALNY Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Zeta Global Holdings Insiders Buy Stock After Short-ReportServiceNow: Will the High-Flyer Finally Split in 2024?Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in Buybacks This page (NASDAQ:SABS) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.